• DIANA assay

    Novel detection assay with unique benefits for in vitro diagnostics and drug discovery.

Introducing DIANA assay

DIANA (DNA-linked Inhibitor ANtibody Assay) is a novel ultra-sensitive multi-well plate based protein detection assay, which provides unique benefits in its two main areas of application:

Screening of chemical libraries for inhibitors or ligands of the target protein with ultra-low false-negative and false-positive rates

Ultra-sensitive detection of active enzymes or receptors in a range of clinical samples

How it works?

DIANA is a multi-well plate assay, where target protein is selectively captured to the solid carrier and then bound by a unique detection probe consisting of a small-molecule ligand linked to a DNA-oligonucleotide. Subsequently, the probe is detected and quantified by qPCR. For drug discovery, the assay utilizes competition between the probe and the test compounds to measure their binding affinity.

DIANA is straightforward to develop for new targets and easy to implement using standard laboratory equipment.

DIANA for drug discovery

  • Quantitative screening of compounds for interactions with the target of interest
  • Sensitive hit discovery with ultra-low false positive and false negative rates
  • Suitable for compound pooling format reducing ~10-times number of wells required
  • Provided as a service or as a screening kit easy to implement at any facility
  • Suitable for both high throughput screening and lead compound optimization

Extremely high signal-to-noise ratio (Z’>0.9;CV<5%)

Quantitative - inhibition potency determined from a single well

Sensitive hit discovery, ultra-low false-positive and false-negative rate

Robust - no need for recombinant or purified proteins

Highly cost-efficient - very low consumption + compatible with pooling

Available as screening kit or as screening service at our facility

DIANA for diagnostics

  • Detection of onco-markers and other relevant protein targets in blood or other clinical samples
  • Ultra-sensitive and quantitative detection with the broad dynamic range
  • Assay to be available in kit format which could be used in any standard laboratory setting
  • Suitable for both R&D and clinical diagnostics applications

Ultra-sensitive (zeptomolar) with broad dynamic range

Very low background – no antibody interference

Highly selective for active form of the target

Works with tiny amounts of different biological samples

CE IVD certification possible

Available in kit format with easy-to-use protocol or as a service

Our R&D pipeline

  • DIANA assay has been already developed and validated for 5 targets in the diagnostic mode and for >10 targets in the screening mode
  • We focus on medically relevant enzymes and receptors (incl. multiple onco-markers)
  • Examples of targets include: Carbonic Anhydrase family, Prostate Specific Membrane Antigene or Insulin receptor
  • In addition to our internal R&D pipeline, we are developing DIANA assays for new targets on demand
  • Development of DIANA assay for a new target is fast and straightforward
TargetDevelopment statusProducts available
Development initiatedProbe synthesized & testedAssay validated - available for licensingScreening
EnzymesProstate specific membrane antigen (PSMA/GCPII) YESYES
Glutamate carboxypeptidase III (GCPIII) YES
Carbonic anhydrase II
Carbonic anhydrase VII YES
Carbonic anhydrase IX YESYES
Carbonic anhydrase XII
Fibroblast activating protein (FAP) YESYES
Neuraminidase N1 strain (A/California/07/2009) YES
RNA polymerase from Influenza A/California/07/2009
17beta-hydroxysteroid dehydrogenase 1 (17beta-HSD1)
DNA methyl transferases
Pan-kinase panel
ReceptorsInsulin receptor YES
Insulin-like growth factor receptors

Our company, team and expertise

DIANA technology was developed by the team lead by Václav Navrátil in the laboratory of Dr. Jan Konvalinka at the Institute of Organic Chemistry and Biochemistry, Academy of Sciences in Prague. This institute has a global reputation and strong record in drug discovery.

In 2018, the spin-off company DIANA Biotechnologies, s.r.o. was established with the venture capital funding in order to deliver DIANA products to the market. The company is based in its own research facility in a biotechnology hub in Vestec near Prague. 

We have assembled a strong team combining deep expertise in molecular biology, organic chemistry, biochemistry, data analysis and technology transfer.

News and upcoming presentations

DIANA Biotechnologies, s.r.o. founded

July 13, 2018

IOCB spin-off company DIANA Biotechnologies, s.r.o. was founded with the significant venture capital funding from the BPD Partners group in order to deliver DIANA products to the market. The company is based in its own research facilities in Vestec near Prague. The company was granted an exclusive license to develop commercial applications based on the DIANA and …

Read more …

DIANA awarded prestigious Werner von Siemens Prize

February 22, 2018

Václav Navrátil’s team has been awarded the prestigious Werner von Siemens Award for 2017 for the development of the DIANA technology. This prize, sponsored by Siemens,  is awarded each year to the best innovation project in the Czech Republic.

Read more …

Meet DIANA at BioFIT 2017 in Strasburg

July 23, 2017

We are presenting DIANA at BioFIT event in Strasburg 28th-29th November 2017. Meet us there to learn about DIANA’s potential and discuss partnership opportunities.

Read more …

Meet DIANA at Bio-Europe 2017 in Berlin

June 6, 2017

We are presenting DIANA at Bio-Europe in Berlin 6th-8th November 2017. Meet us there to learn about DIANA’s potential and discuss partnership opportunities.

Read more …


Navratil et al. (2017): DIANA for sensitive and selective enzyme detection and inhibitor screening. Nucleic Acids research.

Read more …

DIANA for drug discovery – high sensitivity screening of pooled libraries.

Methodology paper in preparation


DIANA Biotechnologies s.r.o.
Nad Safinou II 366
252 50 Vestec
Czech Republic